Adage Capital Partners Gp, L.L.C. Theseus Pharmaceuticals, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$5.04 - $14.05 $3.84 Million - $10.7 Million	-761,589 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.98 - $20.09 $6.84 Million - $15.3 Million	761,589 New	761,589 $9.66 Million

1.06M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.